Abstract

It has been shown that mibefradil (Ro 40-5967) exerts a selective inhibitory effect on T-type Ca²⁺ currents, although at higher concentrations it can antagonize high voltage-activated Ca²⁺ currents. The action of mibefradil on Ca²⁺channels is use- and steady-state-dependent and the binding site of mibefradil on L-type Ca²⁺ channels is different from that of dihydropyridines. By using conventional whole-cell and perforated patch-clamp techniques, we showed that mibefradil has an inhibitory effect on both T- and L-type Ca²⁺currents in insulin-secreting cells. However, the effect on L-type Ca²⁺ currents was time-dependent and poorly reversible in perforated patch-clamp experiments. By using mass spectrometry, we demonstrated that mibefradil accumulates inside cells, and furthermore, a metabolite of mibefradil was detected. Intracellular application of this metabolite selectively blocked the L-type Ca²⁺ current, whereas mibefradil exerted no effect. This study demonstrates that mibefradil permeates into cells and is hydrolyzed to a metabolite that blocks L-type Ca²⁺ channels specifically by acting at the inner side of the channel.